• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    MedTech Pioneer Max Reinhardt Joins eXeX to Drive Canopus Platform Growth

    7/21/26 9:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care
    Get the next $OFIX alert in real time by email

    The Johnson & Johnson, Pacira BioSciences and Orthofix executive takes charge of commercial execution as adoption of Canopus by eXeX accelerates across hospital systems in the United States and United Kingdom, and as eXeX launches Canopus Command, the first portal to give hospital leadership a live operational view into step-by-step execution of every surgical case.

    ORLANDO, Fla. and LONDON, July 21, 2026 /PRNewswire/ -- eXeX, the global Surgery Intelligence company, today announced the appointment of Max Reinhardt as President, Healthcare. Reinhardt, who has held senior leadership roles in MedTech and pharmaceuticals, will drive the company's commercial execution, bringing Surgery Intelligence into hospital systems across the United States, the United Kingdom, and beyond.

    Canopus Command by eXeX

    Canopus™ by eXeX is the world's first Surgery Intelligence platform, designed to transform the experience in the Operating Room (OR) by presenting surgeon, surgery, and OR-specific setup and step-by-step procedure execution plans in real time. Canopus utilizes touch-free technology, digitizing the experience and knowledge of the most capable teams for every OR, every surgeon, and every surgery. The solution reduces surgeon cognitive load, facilitates effective OR teamwork, enables improved OR productivity, and is non-clinical by design, requiring no EHR integration and excluding any patient data for ease of adoption. Canopus optimizes preparation, orchestrates the OR in real time, and turns every case into a planned, structured, informed operation, with the ability for the team to continually optimize the plan as required at any time.

    The appointment caps a period of accelerated quarter-over-quarter growth. Canopus is deployed across multiple hospital groups in the United States and United Kingdom and has supported several thousand live surgeries, proven first where surgery is most complex (spine and orthopedics) and built for all of surgery.

    "The operating room is the most complex workspace on Earth. It deserves intelligent infrastructure, and it deserves leaders who have lived inside it," said Robert Masson, MD, Chairman and CEO of eXeX and a practicing neurological spine surgeon. "Max has spent three decades putting the world's most advanced surgical technology into the hands of teams on every continent. There is no better person to lead our commercial efforts at this exciting time."

    A Career Built in the Operating Room

    Reinhardt brings more than three decades of global MedTech and pharmaceutical executive leadership experience, including seventeen years with Johnson & Johnson. He started with J&J at DePuy Spine in the United Kingdom in 2002 and rose to Vice President of Worldwide Marketing for DePuy Synthes, accountable for $5.5 billion in orthopedics revenue with responsibility for joint reconstruction, trauma, craniomaxillofacial, spine, and sports medicine. His President-level roles span the industry's most competitive categories:

    • President, Global Spine, Orthofix Medical (NASDAQ:OFIX), 2024: leading the company's global spine and biologics business
    • President, Pacira BioSciences 2019: overseeing all commercial and medical affairs
    • Worldwide President, DePuy Synthes Spine (the spine division of Johnson & Johnson) 2013: driving the business to the number-two market-share position in the global spine market
    • Worldwide President, Joint Reconstruction, Sports Medicine & Power Tools, DePuy Synthes, a Johnson & Johnson company

    Earlier in his career, Reinhardt held senior leadership positions with Steris and Olympus in Europe.

    "I have spent thirty years bringing innovation to surgeons and operating rooms globally. eXeX is transforming one of the most complex and demanding work environments - the OR, where planning, communication, teamwork and execution are vital to a great outcome," said Reinhardt. "The best surgical teams in the world run on memory and tribal knowledge. For the first time, that experience and know-how can be captured and delivered, making every case the team's best case. This is a once-in-a-generation shift that is long overdue, and eXeX is leading it."

    Reinhardt joins recently appointed Chief Operating Officer John Spranger to form the leadership team driving Surgery Intelligence. Alongside Dr. Masson, their mandate is to bring Canopus by eXeX to every OR, for every surgeon and every surgery.

    eXeX Launches Canopus Command

    eXeX also announced Canopus Command, an intelligent portal that gives hospital staff and leadership a live operational view inside every case. Every procedure generates operational data (setup accuracy, workflow timing, supply utilization, onboarding velocity) that until now disappeared the moment the case ended. With Canopus Command, hospitals see it in real time.

    At its heart is a breakthrough measurement: the Surgical Inquiry, the discrete moment a team member pulls the exact information they need for the case in front of them. Tracked across a facility, Surgical Inquiries reveal where demand is concentrating (by procedure, by team, and by moment in the workflow) so leadership can move resources and personnel ahead of the need, not after it.

    About eXeX

    eXeX (Expanded Existence, Inc.) is building the operating system for surgery. Founded in 2022 and headquartered in Orlando, Florida, the company has built a patented platform, Canopus by eXeX, that is live across hospital systems in the United States and United Kingdom and expanding worldwide, providing surgical teams with workflow guidance and giving hospital leadership real-time operational visibility into every case. Learn more at exex.ai.

    Media Contact

    Douglas Sonders

    douglas@exex.ai • 703-618-4110

     

    Max Reinhardt of eXeX

    eXeX Company Logo (PRNewsfoto/eXeX)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/medtech-pioneer-max-reinhardt-joins-exex-to-drive-canopus-platform-growth-302830852.html

    SOURCE eXeX

    Get the next $OFIX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OFIX

    DatePrice TargetRatingAnalyst
    1/27/2026$14.00Hold
    TD Cowen
    10/28/2025$22.00Buy
    Stifel
    1/22/2025$24.00Buy
    Canaccord Genuity
    11/8/2024$18.00 → $24.00Hold → Buy
    Stifel
    5/8/2024$15.00 → $20.00Neutral → Buy
    ROTH MKM
    10/20/2023$12.00Neutral
    ROTH MKM
    9/12/2023Buy → Neutral
    BTIG Research
    9/12/2023Buy → Hold
    Stifel
    More analyst ratings

    $OFIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MedTech Pioneer Max Reinhardt Joins eXeX to Drive Canopus Platform Growth

    The Johnson & Johnson, Pacira BioSciences and Orthofix executive takes charge of commercial execution as adoption of Canopus by eXeX accelerates across hospital systems in the United States and United Kingdom, and as eXeX launches Canopus Command, the first portal to give hospital leadership a live operational view into step-by-step execution of every surgical case.ORLANDO, Fla. and LONDON, July 21, 2026 /PRNewswire/ -- eXeX, the global Surgery Intelligence company, today announced the appointment of Max Reinhardt as President, Healthcare. Reinhardt, who has held senior leadership roles in MedTech and pharmaceuticals, will drive the company's commercial execution, bringing Surgery Intelligen

    7/21/26 9:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix to Participate in Upcoming Investor Conferences

    Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Orthofix will participate in the following investor conferences: Needham Virtual MedTech & Diagnostics 1x1 Conference - Virtual, August 10, 2026, 1x1 Meetings Canaccord Genuity’s 46th Annual Growth Conference - Boston, August 12, 2026, Fireside Chat Time: 9:30 am Eastern Time Interested parties can access the live and archived webcast of the Canaccord Genuity fireside chat in the "Events & Presentations" section of the Orthofix Investor Relations Website at ir.orthofix.com. Internet Posting of Information Orthofix regularly shares important updates in the "Investors" section o

    7/20/26 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix to Report Second Quarter 2026 Financial Results

    Company to Host Conference Call on Wednesday, August 5, 2026, at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 8700861. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting o

    7/15/26 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    SEC Filings

    View All

    Orthofix Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Orthofix Medical Inc. (0000884624) (Filer)

    7/2/26 4:00:15 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix Medical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Orthofix Medical Inc. (0000884624) (Filer)

    6/11/26 7:01:40 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by Orthofix Medical Inc.

    SD - Orthofix Medical Inc. (0000884624) (Filer)

    5/29/26 10:13:47 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Henneman John B Iii bought $61,295 worth of shares (5,000 units at $12.26), increasing direct ownership by 6% to 90,809 units (SEC Form 4)

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    5/8/26 4:52:20 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Large owner Engine Capital Management, Lp bought $2,232,927 worth of shares (184,896 units at $12.08) (SEC Form 4)

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    5/7/26 6:15:58 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Director Capps Vickie L bought $62,324 worth of shares (5,000 units at $12.46), increasing direct ownership by 22% to 27,585 units (SEC Form 4)

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    3/10/26 4:13:55 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Orthofix with a new price target

    TD Cowen initiated coverage of Orthofix with a rating of Hold and set a new price target of $14.00

    1/27/26 8:48:16 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Stifel resumed coverage on Orthofix with a new price target

    Stifel resumed coverage of Orthofix with a rating of Buy and set a new price target of $22.00

    10/28/25 7:09:19 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Canaccord Genuity initiated coverage on Orthofix with a new price target

    Canaccord Genuity initiated coverage of Orthofix with a rating of Buy and set a new price target of $24.00

    1/22/25 7:47:50 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Pres, Global Ops & Qual Mcpherron Aviva sold $34,425 worth of shares (3,670 units at $9.38), decreasing direct ownership by 5% to 66,330 units (SEC Form 4) to cover withholding tax

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    6/22/26 4:14:59 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Director Bazaar Alan Lee was granted 14,965 shares, increasing direct ownership by 30% to 65,489 units (SEC Form 4)

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    6/12/26 6:31:41 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Director Kummeth Charles R. was granted 14,965 shares, increasing direct ownership by 24% to 76,305 units (SEC Form 4)

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    6/12/26 6:30:54 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Financials

    Live finance-specific insights

    View All

    Orthofix to Report Second Quarter 2026 Financial Results

    Company to Host Conference Call on Wednesday, August 5, 2026, at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 8700861. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting o

    7/15/26 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix Reports First Quarter 2026 Results Highlighting Steady Execution Following Spine Commercial Channel Actions; Reaffirms Full-Year 2026 Financial Guidance

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2026, reflecting steady execution following recent spine commercial channel actions. Based on first-quarter performance, the Company reaffirmed its full-year 2026 financial guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6™ product lines. Highlights First quarter 2026 reported net sales of $196.7 million, including sales from M6 artificial cervical and lumbar discs. Non-GAAP pro forma net sales of $196.4 million, excluding sales from M6 discs, incre

    5/5/26 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix to Report First Quarter 2026 Financial Results

    Company to Host Conference Call on Tuesday, May 5, 2026, at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 7578740. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of Informati

    4/21/26 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Leadership Updates

    Live Leadership Updates

    View All

    MedTech Pioneer Max Reinhardt Joins eXeX to Drive Canopus Platform Growth

    The Johnson & Johnson, Pacira BioSciences and Orthofix executive takes charge of commercial execution as adoption of Canopus by eXeX accelerates across hospital systems in the United States and United Kingdom, and as eXeX launches Canopus Command, the first portal to give hospital leadership a live operational view into step-by-step execution of every surgical case.ORLANDO, Fla. and LONDON, July 21, 2026 /PRNewswire/ -- eXeX, the global Surgery Intelligence company, today announced the appointment of Max Reinhardt as President, Healthcare. Reinhardt, who has held senior leadership roles in MedTech and pharmaceuticals, will drive the company's commercial execution, bringing Surgery Intelligen

    7/21/26 9:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Fox Factory Announces Strategic Board Refresh

    Company to Appoint Two New Independent Directors and Form Transformation Committee Focused on Operational Excellence and Margin Improvement Company Enters into Cooperation Agreement with Engine Capital DULUTH, Ga., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Fox Factory Holding Corp. (Nasdaq: FOXF) ("Fox Factory" or the "Company"), a premium brand and a global leader in the design, engineering and manufacturing of performance-defining products and systems for customers worldwide, today announced that following constructive discussions with Engine Capital ("Engine Capital") regarding opportunities to enhance operational performance and profitability, the Company will be undertaking a strategic boar

    2/9/26 4:05:00 PM ET
    $FOXF
    $OFIX
    Motor Vehicles
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m

    1/9/26 7:00:00 AM ET
    $AVNS
    $HYPR
    $OFIX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    $OFIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Orthofix Medical Inc.

    SC 13G/A - Orthofix Medical Inc. (0000884624) (Subject)

    11/14/24 5:20:27 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Orthofix Medical Inc.

    SC 13G - Orthofix Medical Inc. (0000884624) (Subject)

    11/13/24 5:03:21 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Orthofix Medical Inc. (Amendment)

    SC 13D/A - Orthofix Medical Inc. (0000884624) (Subject)

    4/22/24 5:00:33 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care